STOCK TITAN

Syndax Announces Participation in BTIG Virtual Biotechnology Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq:SNDX) announced participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:00 p.m. ET. The company's management team will engage in a virtual fireside chat, and a live webcast will be available on its investor website, with a replay accessible temporarily. Syndax is focused on developing innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat. For further details, visit www.syndax.com.

Loading...
Loading translation...
Argus Session date unavailable
+3.47% session move Open Argus
Details

News Market Reaction – SNDX

The recorded move for SNDX in the trading session of this news was +3.47%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.      

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

Cision View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-in-btig-virtual-biotechnology-conference-301104238.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event is Syndax Pharmaceuticals participating in on August 10, 2020?

Syndax Pharmaceuticals will participate virtually in the BTIG Biotechnology Conference on August 10, 2020.

What time will Syndax's presentation at the BTIG Conference take place?

The presentation by Syndax Pharmaceuticals at the BTIG Conference will take place at 12:00 p.m. ET.

How can I access the live webcast of Syndax's presentation?

The live webcast of Syndax's presentation can be accessed from the investor section of their website.

What is the focus of Syndax Pharmaceuticals' development?

Syndax Pharmaceuticals focuses on developing innovative cancer therapies.

Keep reading